Pulike Biological Engineering (SHSE:603566) Beneish M-Score: -2.58 (As of Jul. 07, 2026)


SHSE:603566 Pulike Biological Engineering Inc SHSE:603566
64 GF Score
Price ¥10.24
GF Value ¥14.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Pulike Biological Engineering Beneish M-Score?

Pulike Biological Engineering SHSE:603566 -2.94% 64 Beneish M-Score is -2.58 as of Jul. 07, 2026. GuruFocus rates SHSE:603566 with a GF Score™ of 64/100 and a GF Value™ of ¥14.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 824 Biotechnology companies, Pulike Biological Engineering ranks better than 59.59% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.58 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pulike Biological Engineering's Beneish M-Score or its related term are showing as below:

SHSE:603566' s Beneish M-Score Range Over the Past 10 Years
Min: -3.09   Med: -2.45   Max: -1.83
Current: -2.58

During the past 13 years, the highest Beneish M-Score of Pulike Biological Engineering was -1.83. The lowest was -3.09. And the median was -2.45.


Pulike Biological Engineering Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Pulike Biological Engineering's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pulike Biological Engineering Beneish M-Score Chart

Pulike Biological Engineering Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.15 -2.20 -2.67 -2.88 -2.77

Pulike Biological Engineering Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.87 -3.08 -3.09 -2.77 -2.58

SHSE:603566 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Pulike Biological Engineering's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulike Biological Engineering Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pulike Biological Engineering's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pulike Biological Engineering's Beneish M-Score falls into.


SHSE:603566
64GF Score
Pulike Biological Engineering Inc SHSE:603566
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pulike Biological Engineering Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pulike Biological Engineering for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1209+0.528 * 1.0217+0.404 * 0.7971+0.892 * 0.9768+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8573+4.679 * -0.031114-0.327 * 1.0037
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥410 Mil.
Revenue was 249.24 + 266.865 + 263.583 + 280.81 = ¥1,060 Mil.
Gross Profit was 136.82 + 154.975 + 163.224 + 167.958 = ¥623 Mil.
Total Current Assets was ¥1,406 Mil.
Total Assets was ¥3,217 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,264 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥193 Mil.
Total Current Liabilities was ¥368 Mil.
Long-Term Debt & Capital Lease Obligation was ¥20 Mil.
Net Income was 40.734 + 27.858 + 40.953 + 63.274 = ¥173 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -36.519 + 78.673 + 82.598 + 148.17 = ¥273 Mil.
Total Receivables was ¥375 Mil.
Revenue was 278.619 + 280.82 + 278.59 + 247.662 = ¥1,086 Mil.
Gross Profit was 166.372 + 155.917 + 175.747 + 153.586 = ¥652 Mil.
Total Current Assets was ¥1,293 Mil.
Total Assets was ¥3,094 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,142 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥231 Mil.
Total Current Liabilities was ¥372 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(410.358 / 1060.498) / (374.808 / 1085.691)
=0.386948 / 0.345225
=1.1209

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(651.622 / 1085.691) / (622.977 / 1060.498)
=0.600191 / 0.587438
=1.0217

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1406.478 + 1264.082) / 3217.27) / (1 - (1292.964 + 1141.781) / 3094.448)
=0.16993 / 0.213189
=0.7971

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1060.498 / 1085.691
=0.9768

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1141.781)) / (0 / (0 + 1264.082))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(193.181 / 1060.498) / (230.683 / 1085.691)
=0.182161 / 0.212476
=0.8573

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((20.426 + 368.262) / 3217.27) / ((0.174 + 372.301) / 3094.448)
=0.120813 / 0.120369
=1.0037

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(172.819 - 0 - 272.922) / 3217.27
=-0.031114

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pulike Biological Engineering has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.58 mean?
Pulike Biological Engineering (SHSE:603566) has a Beneish M-Score of -2.58 as of Jul. 07, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pulike Biological Engineering and its competitors. According to the industry distribution chart, Pulike Biological Engineering ranks #333 out of 824 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Pulike Biological Engineering's Beneish M-Score too high?
Pulike Biological Engineering's current Beneish M-Score is -2.58. Based on the distribution chart, Pulike Biological Engineering ranks #333 out of 824 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pulike Biological Engineering has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pulike Biological Engineering's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pulike Biological Engineering ranks #333 out of 824 companies for Beneish M-Score. This puts Pulike Biological Engineering in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Pulike Biological Engineering and its competitors. Pulike Biological Engineering's current Beneish M-Score is -2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulike Biological Engineering stock overvalued right now?
Based on GuruFocus' analysis, Pulike Biological Engineering (SHSE:603566) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.18, compared to a current price of ¥10.24 — trading 27.8% below its estimated fair value. The current Beneish M-Score is -2.58. Pulike Biological Engineering's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Pulike Biological Engineering (SHSE:603566), the current Beneish M-Score is -2.58 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pulike Biological Engineering (SHSE:603566) Overvalued in 2026?

Based on GuruFocus' analysis, Pulike Biological Engineering stock appears to be undervalued. The current stock price of ¥10.24 is trading 27.8% below its estimated GF Value™ of ¥14.18. GuruFocus considers Pulike Biological Engineering to be Modestly Undervalued.

Key valuation signals for SHSE:603566:

  • Beneish M-Score: -2.58
  • GF Value™: ¥14.18 vs. price of ¥10.24 (27.8% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603566 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pulike Biological Engineering Business Description

Address 15th New governance, Henan Province, Luoyang, CHN, 471000
Pulike Biological Engineering Inc is engaged in the research and development and production and operation of veterinary drugs.
64GF Score

Get the complete analysis for SHSE:603566

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.24
Price
¥14.18
GF Value